Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer

https://doi.org/10.1016/S0093-7754(01)90058-2Get rights and content

Abstract

Non-small cell lung cancer (NSCLC) is a systemic illness. The majority of newly diagnosed patients depend on systemic chemotherapy to improve outcome. Among the new chemotherapeutic agents recently tested, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has shown convincing single-agent activity in advanced NSCLC. The two initial phase II studies using paclitaxel alone showed a 1-year survival rate of 40%, comparable to that seen with combination regimens. Paclitaxel/carboplatin is one of several standard regimens for patients with stage IIIB to IV disease. It is as effective as any other new agent/platinum combination studied to date; it is easy to administer and well tolerated. Identification of the molecular and genetic events involved in each step of tumor progression seems to be crucial both to understanding lung cancer and for the development of new pharmacologic compounds that target specific cellular processes affecting growth and proliferation. An innovative strategy is to combine established chemotherapy with these new compounds. Resistance to available chemotherapy drugs is the major obstacle to effective chemotherapy. Genetic abnormalities could play a role in outlining some patterns of chemoresistance. Acquired resistance to paclitaxel can be mediated by several mechanisms, including overexpression of p-glycoprotein, altered expression of β-tubulin isotypes, intrinsic or acquired mutations in β-tubulin, and expression of novel genes. Beta-tubulin mutations were recently identified in 33% of 49 NSCLC patients, none of whom had an objective response to paclitaxel treatment. Cisplatin resistance is associated with several molecular alterations, including overexpression of metallothionein and the mRNA level of the excision repair cross-complementing (ERCCI) gene. Early detection of circulating cancer cells in peripheral blood would enable more accurate lung cancer staging. Furthermore, sequential measurements of DNA concentration may be used to monitor the effects of therapy. Serum DNA can be used as a surrogate for detecting genetic abnormalities and as a potential guide for customizing treatment. We analyzed the presence of β-tubulin mutations in serum DNA from NSCLC patients and from healthy individuals. Beta-tubulin mutations were detected in 42% of the 131 patients and in none of the control group. Several clinical studies are proposed to develop more customized approaches in lung cancer.

References (56)

  • WK Murphy et al.

    Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer

    J Natl Cancer Inst

    (1993)
  • R Rosell et al.

    Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: Links between p53 and K-ras gene status and chemosensitivity

  • M Ranson et al.

    Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer

    J Natl Cancer Inst

    (2000)
  • R Rosell et al.

    Paclitaxel plus carboplatin in advanced non-small-cell lung cancer

    Oncology

    (1999)
  • CJ Langer et al.

    Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response and survival analysis

    J Clin Oncol

    (1995)
  • DH Johnson et al.

    Paclitaxel plus carboplatin in advanced non-small cell lung cancer: A phase II trial

    J Clin Oncol

    (1996)
  • RB Natale

    Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small-cell lung cancer

  • MT Huizing et al.

    Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-smallcell lung cancer

    J Clin Oncol

    (1997)
  • K Kelly et al.

    A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer

    Clin Cancer Res

    (1997)
  • P Kosmidis et al.

    Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: A randomized study

  • G Giaccone et al.

    Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

    J Clin Oncol

    (1998)
  • CP Belani et al.

    Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC)

  • P Bonomi et al.

    Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial

    J Clin Oncol

    (2000)
  • F Cardenal et al.

    Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer

    J Clin Oncol

    (1999)
  • K Kelly et al.

    A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial

  • U Gatzemeier et al.

    Randomized pan-European trial comparing paclitaxel (TAX)/carboplatin versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC)

    Eur J Cancer

    (1999)
  • JH Schiller et al.

    A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)

  • FA Shepherd et al.

    Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy

    J Clin Oncol

    (2000)
  • Cited by (34)

    • Photodynamic effect of chlorin e6 on cytoskeleton protein of human colon cancer SW480 cells

      2021, Photodiagnosis and Photodynamic Therapy
      Citation Excerpt :

      It will directly affect the formation of spindle in mitosis and the cells cannot divide normally if microtubule de-polymerization or α and β protein polymerization was destroyed, and tubulin plays a key role in this process [22]. Some studies have found that the abnormal expression of tubulin will lead to the occurrence of malignant behaviors such as abnormal cell proliferation, invasion and metastasis which can be found in many kinds of tumor tissues like gastric cancer, rectal cancer, prostate cancer and lung cancer [23–26]. Our study of western blot demonstrated that the expression of α-tubulin and β-tubulin in SW480 cells decreased significantly after Ce6-PDT (Fig.5).

    • Raloxifene-encapsulated hyaluronic acid-decorated chitosan nanoparticles selectively induce apoptosis in lung cancer cells

      2019, Bioorganic and Medicinal Chemistry
      Citation Excerpt :

      Thus, a better understanding of carcinogenic machineries and mechanisms of drug resistance is pivotal for current drug development plans.1,6 In contemporary studies, specific mutagenic inhibitors have been exploited in lung cancer treatment; however, these therapeutic strategies are only suitable for specific rare mutagenic cases,7,8 of which the majority eventually develop chemo-resistance.9 Therefore, there is an urgent need for the development of new therapeutic approaches for NSCLC.

    • Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer

      2010, Critical Reviews in Oncology/Hematology
      Citation Excerpt :

      In NSCLC patients treated with surgery alone, high class III β-tubulin expression was associated with poorer relapse-free and overall survival [290]. In locally advanced or metastatic NSCLC treated with taxane-containing regimens, patients with tumor β-tubulin mutations had substantially lower response rates [288] or a trend towards lower response rates [287] than did patients with wild type β-tubulin. Response rates were also lower in patients with high tumor expression of β-tubulin III compared to those with low expression [291,292].

    • The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer

      2007, Journal of Thoracic Oncology
      Citation Excerpt :

      Therefore, the mutational and gene expression analysis of tubulin isotypes could be of critical importance in assessing the sensitivity of cancer cells toward taxanes. β tubulin class I mutation had been described in patients with NSCLC 26 and was identified in 33% of patients with NSCLC, none of whom had an objective response to paclitaxel treatment.27 The up-regulation of βIII isotype is another important marker of resistance, and high concentrations of βIII-tubulin are associated with a decrease in paclitaxel sensitivity in NSCLC cells.

    • Additive Effects of TRAIL and Paclitaxel on Cancer Cells: Implications for Advances in Cancer Therapy

      2004, Vitamins and Hormones
      Citation Excerpt :

      One possible new strategy in the cancer treatment is to combine chemotherapeutic agents with proapoptotic genes or molecules to enhance the apoptotic death of tumor cells. Through many clinical trials, PA antitumor activity has been observed and improved by its combination with several known antitumor drugs, such as platinum, carboplatin, anthracyclins, doxorubicin, cisplatin, or docetaxel (Belani, 2000; Bunn, Jr. et al., 2000; Nabholtz et al., 2001; Novello et al., 2001; Perez, 2001; Rosell et al., 2001). New agents, such as antibodies, or modified genes are also presently investigated (Perez, 1999).

    View all citing articles on Scopus
    1

    Dr Rosell has received research grant support from the Bristol-Myers Squibb COMET Program.

    View full text